Sarclisa gains European nod for first-line multiple myeloma

French pharma giant Sanofi (Euronext: SAN) has secured European Union approval for Sarclisa (isatuximab) for certain people with newly diagnosed multiple myeloma.

The nod covers treatment with the antibody, in combination with VRd, for people who are ineligible for autologous stem cell transplant.

The approval, based on findings from the Phase III IMROZ study, positions Sarclisa as the first anti-CD38 plus VRd combo for this patient population in the EU, giving Sanofi a boost in its competition with Johnson & Johnson’s (NYSE: JNJ) Darzalex (daratumumab).